Sonnet BioTherapeutics to Join Upcoming Investor Series
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) is thrilled to announce its participation in an upcoming virtual investor event. This opportunity is designed to provide valuable insights into their groundbreaking work in developing targeted immunotherapeutic drugs.
Details of the Event
The Virtual Investor Closing Bell Series is set for September 9, 2024, at 4:00 PM ET. Pankaj Mohan, the Founder and CEO of Sonnet BioTherapeutics, will lead the event, offering a thorough overview of the company and discussing its business outlook. This will be more than just a presentation; the event will feature a moderated discussion, allowing investors to ask questions live or submit them in advance to foster engagement.
How to Participate in the Event
Investors interested in engaging during the event can submit their questions live. Additionally, they have the option to pre-submit their inquiries via email as the event date approaches. This interactive approach is intended to ensure that all participants can gain valuable insights and have their questions addressed by Sonnet's leadership team.
Accessing the Live Presentation
For those unable to attend the live event, a webcast will be available on the Company’s website under the Events page. After the presentation, a replay will be accessible for 90 days, allowing broader access to the information shared during the event. This flexibility ensures that everyone interested can stay updated on the latest developments at Sonnet BioTherapeutics.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is committed to the oncology field, focusing on the development of innovative biologic drugs through its proprietary technology platform known as FHAB (Fully Human Albumin Binding). This distinctive approach utilizes fully human single chain antibody fragments to enhance the targeted delivery of therapeutics directly to tumor and lymphatic tissues. Sonnet's technology aims to improve the therapeutic window of immune-modulating biologic drugs, optimizing both safety and efficacy.
Contact Information
For additional inquiries, investors can reach out to the Investor Relations contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
SONN@jtcir.com
Frequently Asked Questions
What is the focus of Sonnet BioTherapeutics?
Sonnet BioTherapeutics specializes in developing targeted immunotherapeutic drugs, particularly in the field of oncology.
When is the Virtual Investor Closing Bell Series?
The event will take place on September 9, 2024, at 4:00 PM ET.
How can investors participate in the event?
Investors can engage by asking questions live during the presentation or by submitting them in advance via email.
Where can I watch the live presentation?
The live presentation will be available on the Events page of the Sonnet BioTherapeutics website, with a replay accessible for 90 days after the event.
What technology does Sonnet BioTherapeutics use?
Sonnet employs a proprietary technology called FHAB, which enables targeted drug delivery using human serum albumin to enhance therapeutic outcomes.